Literature DB >> 1752486

Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging.

M Monga1, J A Carmichael, W E Shelley, M E Kirk, G V Krepart, J F Jeffrey, J L Pater.   

Abstract

From January 1981 to December 1987, 82 patients with carcinoma of the ovary, Stages 1A, 1B, and 1C (cytology negative) (FIGO 1988), were enrolled in this study following accurate surgical staging. No patient received adjunctive therapy and all were followed from 2 to 6 years with a mean duration of follow-up of 4 years. Sixty-eight patients were eligible for review--thirty-nine Stage 1A, six Stage 1B, and twenty-three Stage 1C (twenty-one with tumor rupture, two with excrescences). The mean age was 48.8 years. Three patients had a recurrence of their disease (one death). Forty patients in this series were Stage 1A or 1B (well or moderately well differentiated, no excrescences, no rupture). Only 1 patient in this group (with clear cell carcinoma) has recurred, suggesting that this patient population can be followed without adjunctive therapy. Adhesions or rupture in this series did not affect outcome. Clear cell tumors may have an ominous prognosis despite apparent local disease.

Entities:  

Mesh:

Year:  1991        PMID: 1752486     DOI: 10.1016/0090-8258(91)90018-z

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Clinical and prognostic value of the presence of irregular giant nuclear cells in pT1 ovarian clear cell carcinoma.

Authors:  Naoki Matsumoto; Takashi Umezawa; Toru Sasaki; Kuninobu Nakajima; Yukiko Kanetsuna; Hiroshi Sasaki
Journal:  Pathol Oncol Res       Date:  2011-01-28       Impact factor: 3.201

2.  Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells.

Authors:  Nao Suzuki; Atsushi Higashiguchi; Yuko Hasegawa; Hiroshi Matsumoto; Shinji Oie; Kimiko Orikawa; Sachiko Ezawa; Nobuyuki Susumu; Ki-Ichi Miyashita; Daisuke Aoki
Journal:  Hum Cell       Date:  2005-09       Impact factor: 4.174

Review 3.  Role of minimally invasive surgery in early ovarian cancer.

Authors:  Chul Kwon Lim; Dae Yeon Kim; Angela Cho; Ji-Yeong Choi; Jeong-Yeol Park; Yong-Man Kim
Journal:  Gland Surg       Date:  2021-03

4.  Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

Authors:  Hal W Hirte
Journal:  Onco Targets Ther       Date:  2013-04-18       Impact factor: 4.147

5.  Comparison of Laparoscopy and Laparotomy in Surgical Staging of Apparent Early Ovarian Cancer: 13-year Experience.

Authors:  Qi Lu; Hong Qu; Chongdong Liu; Shuzhen Wang; Zhiqiang Zhang; Zhenyu Zhang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.